following a full submission:
imiquimod (Zyclara®) is accepted for restricted use within NHSScotland.
Indication under review: for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.
SMC restriction: for the treatment of large field actinic keratosis (>25cm2).
In two randomised, double-blind, phase III studies, a greater proportion of adults with actinic keratosis affecting an area >25cm2 on the face or balding scalp achieved complete clearance when treated with imiquimod 3.75% cream compared with vehicle.
Medicine details
- Medicine name:
- imiquimod (Zyclara)
- SMC ID:
- SMC2211
- Indication:
Topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.
- Pharmaceutical company
- Meda Pharmaceuticals Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 11 November 2019